<DOC>
	<DOCNO>NCT02406742</DOCNO>
	<brief_summary>Safety , pharmacokinetics , preliminary efficacy CC-122 alone combination ibrutinib obinuzutumab . CC-122 multiple activity , include immune modulation several immune cell subset antiproliferative activity CLL . CC-122 also show tolerable safety profile preliminary sign efficacy early human experience .</brief_summary>
	<brief_title>A Phase 1/2 , Open-label , Dose Finding Study Evaluate CC-122 Combination With Ibrutinib Obinutuzumab Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>The primary objective Phase 1/2 Study determine safety single agent CC-122 safety , tolerability , RP2D CC-122 administer combination ibrutinib combination obinutuzumab subject CLL/SLL . The secondary objective evaluate PK profile subject administer CC-122 combination ibrutinib combination obinutuzumab , determine ibrutinib concentration give alone combination CC-122 evaluate preliminary efficacy CC-122 select dose levels/regimens .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>1 . Subjects ≥ 18 year age ≤ 80 year age time sign informed consent form . 2 . Understand voluntarily sign informed consent form prior study related assessments/procedures conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . Must document diagnosis CLL/ SLL require treatment ( per IWCLL guideline ) . In addition : . Presence least one clinically measurable lesion : i. nodal lesion measure ≥ 1.5 cm long dimension ( LD ) ≥ 1.0 cm long perpendicular dimension ( LPD ) , ii . spleen measure ≥ 14 cm long vertical dimension ( LVD ) minimum 2 cm enlargement , iii . liver measure ≥ 20 cm LVD minimum 2 cm enlargement , iv . peripheral blood B lymphocyte count &gt; 5000/uL . 5 . Must meet criterion relapse and/or refractory disease accord IWCLL guideline ( Hallek , 2008 ) ≥ 1 prior treatment ( exception Arm B ) evidence disease progression require treatment time study entry follow : . For Arms A C , subject must receive either prior chemoimmunotherapy therapy approve BTK inhibitor follow exception : i. Chemoimmunotherapy require subject specific comorbidities preclude use standard chemoimmunotherapy meeting least 1 follow criterion ; 1 . CIRS ≥ 6 ; 2 . Creatinine Clearance &lt; 70 mL/min ; 3 . Subject candidate chemoimmunotherapy opinion investigator . ii . Treatment approve BTK inhibitor require subject contraindication candidate therapy opinion investigator . b . For Arm B , subject treatmentnaïve R/R CLL must meet following criterion : . Dose Escalation Phase : Subjects must receive prior treatment ibrutinib ( approve BTK inhibitor ) must either R/R CLL treatment naïve ( ie , firstline ) CLL subject : 1. 17p and/or TP53 mutation ; 2. unfit standard chemoimmunotherapy meeting least 1 follow comorbidity criterion : a. CIRS ≥ 6 ; b. Creatinine Clearance &lt; 70 mL/min ; c. Subject candidate chemoimmunotherapy opinion investigator . The reason candidate must document CRF . ii . Dose Expansion Phase : Subjects must receive prior treatment ibrutinib ( approve BTK inhibitor ) must high risk CLL . High risk define : 1 ) 17p and/or TP53 mutation positive treatment naïve CLL ; 2 ) 17p and/or TP53 mutation positive , and/or complex karyotype , and/or progression &lt; 24 month completion 1st line chemoimmunotherapy R/R CLL c. Subjects R/R SLL CLL bulky disease ( least one lymph node measure &gt; 5.0 cm diameter ) consider high risk develop TFR may enrol upon discussion sponsor 's medical monitor agreement close medical management . 6 . Subjects must follow lab value : 1 . Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm3 ≥ 1000 cells/mm3 secondary bone marrow involvement disease . 2 . Platelet count ≥ 100,000 cells/mm3 ( 100 x 109/L ) ≥ 50,000 cells/mm3 ( 50 x 109/L ) secondary bone marrow involvement disease . 3 . Serum aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) &lt; 3.0 x upper limit normal ( ULN ) unless due disease . 4 . Serum bilirubin &lt; 1.5 x ULN unless due Gilbert 's syndrome . Serum bilirubin ≤ 1.0 x ULN unless due Gilbert 's syndrome , Treatment Arm B ( CC122 combination ibrutinib ) 5 . Calculated creatinine clearance ≥ 60 ml/min . 6 . No evidence TLS per CairoBishop definition laboratory TLS ( subject may enrol upon correction electrolyte abnormality ) . 7 . ECOG PS ( Eastern Cooperative Group Performance Status ) 0 1 . 8 . Ability swallow oral capsule without difficulty . 9 . Pregnancy Prevention Risk Management Plan : 1 . Females childbearing potential ( FCBP ) must undergo pregnancy test base frequency outline Pregnancy Prevention Risk Management Plan ( PPRMP ) pregnancy result must negative . 2 . Unless practice complete abstinence heterosexual intercourse , sexually active FCBP must agree use adequate contraceptive method specify PPRMP . *For Arm C , subject must agree use adequate contraceptive method 18 month ( please refer obinutuzumab IB , PI , SmPC ) . Complete abstinence acceptable case prefer usual lifestyle subject . Periodic abstinence ( calendar ovulation , symptothermal , postovulation method ) withdrawal acceptable . 3 . Males ( include vasectomy ) must practice complete abstinence use barrier contraception ( condom ) engage sexual activity FCBP specify PPRMP . 4 . Males must agree donate semen sperm duration study 3 month last dose CC122 . 5 . All subject must : Understand ( investigational Product ) IP could potential teratogenic risk . Agree abstain donate blood take IP follow discontinuation IP . Agree share IP another person . 6 . Other subject , FCBP males handle IP touch capsule , unless glove wear . 7 . Be counseled pregnancy precaution risk fetal exposure . ARM B ONLY : 10 . Enrollment Arm B permit ibrutinib consider standard care clinical practice . EXPANSION COHORT 2 OF ARM C : 11 . Subjects Cohort 2 Arm C must meet following criterion : 1 . Subject must receive least one BCR PI ( ibrutinib , idelalisib , approve BTK PI3K inhibitor ) and/or venetoclax ; 2 . Subject must either resistant intolerant ( ie. , treatment failure ) last BCR PI and/or venetoclax . Resistant define relapsed refractory per IWCLL2008 : i. Relapse define patient previously achieve CR PR , period 6 month , demonstrate evidence disease progression . ii . Refractory define fail achieve CR PR , disease progression within 6 month initiation treatment approve BTK PI3K inhibitor ( eg , ibrutinib , idelalisib ) venetoclax . iii . Intolerance define inability continue treatment BCR PI venetoclax due toxicity due development contraindication make subject ineligible receive treatment BCR PI venetoclax . 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Any condition confound ability interpret data study . 4 . Prior autologous allogeneic stem cell transplant ( SCT ) /bone marrow transplant within 12 month sign ICD . Subjects receive allogeneic SCT ≥ 12 month sign ICD may eligible provided ongoing graftversushost disease ongoing immune suppression therapy . 5 . Uncontrolled intercurrent illness include , limited : 1 . Ongoing active infection require parenteral antibiotic . 2 . Uncontrolled diabetes mellitus . . The glycemic target subject diabetes take consideration age , comorbidities , life expectancy , functional status subject follow establish guideline ( eg , International Diabetes Federation , European Diabetes Working Party guideline , American Diabetes Association ) . For young ( &lt; 70 year old ) subject life expectancy ≥ 10 year , target glycosylated hemoglobin , type A1C ( HbA1c ) &lt; 7.0 % . The target HbA1c older ( ≥ 70 year old ) subject subject life expectancy &lt; 10 year &lt; 8.0 % . Consultation endocrinologist recommend decide diabetes optimally control . c. Chronic symptomatic congestive heart failure ( Class III IV New York Heart Association Classification Heart Disease ) . d. Active central nervous system involvement document spinal fluid cytology image . e. Uncontrolled autoimmune hemolytic anemia thrombocytopenia . f. Other concurrent severe and/or uncontrolled concomitant medical condition could cause unacceptable safety risk compromise compliance protocol . 6 . History second malignancy life expectancy &lt; 2 year requirement therapy would confound study result . This include follow : 1 . Basal cell carcinoma skin . 2 . Squamous cell carcinoma skin . 3 . Carcinoma situ cervix . 4 . Carcinoma situ breast . 5 . Carcinoma situ bladder . 6 . Incidental histologic find prostate cancer ( TNM stage T1a T1b ) . 7 . Known seropositivity history active viral infection human immunodeficiency virus ( HIV ) , hepatitis B C virus ( HBV , HCV ) . . Hepatitis B screen mandatory patient ( HBsAg antiHBc ) . Patients active hepatitis B disease treat obinutuzumab . Patients refer specialist carrier treatment start ( see PI SmPC ) . Subjects positive antiHBc and/or antiHBs negative HBsAg HBV DNA may treat consultation hepatologist . 8 . Any peripheral neuropathy ≥ NCI CTCAE Grade 2 . 9 . Use systemic corticosteroid dos great prednisone equivalent 20 mg/day . 10 . Medicines high probability cause QT prolongation torsades de pointes . Subjects chronic medication category may enroll discussion medical monitor change medication best medical interest patient . 11 . History hypersensitivity IMiDs® ( lenalidomide , pomalidomide , thalidomide ) . 12 . Impaired cardiac function clinically significant cardiac disease , include follow : 1 . Left ventricular ejection fraction ( LVEF ) &lt; 45 % determine MUGA scan echocardiogram ( ECHO ) . 2 . Complete leave bundle branch , bifasicular , block . 3 . Congenital long QT syndrome . 4 . Persistent uncontrolled ventricular arrhythmias atrial fibrillation . 5 . QTcF &gt; 470 msec Screening ECG ( mean triplicate recording ) . 6 . Unstable angina pectoris myocardial infarction ≤ 6 month prior start CC 122 . 7 . Uncontrolled congestive heart failure uncontrolled hypertension . 8 . TroponinT value &gt; 0.4 ng/mL BNP &gt; 300 pg/mL . Subjects baseline troponinT &gt; ULN BNP &gt; 100 pg/mL eligible must cardiologist evaluation prior enrollment trial baseline assessment optimization cardioprotective therapy . 13 . Chemotherapy , radiotherapy , investigational anticancer therapy major surgery within 28 day Day 1 dose follow exception : . Arm A : A minimum 5day washout discontinuation ibrutinib therapy ( BTK inhibitor ) require ; subject without rapid disease progression 5day washout allow enroll Arm A. . Rapid disease progression define follow : 1 . For subject measurable nodal disease , increase sum diameter large lymph node ( 3 node ) exceed 1 cm per day OR diameter large lymph node exceed 5 cm 5 day wash . 2 . For subject lymphocytosis , increase ALC exceed 2x109/L per day OR ALC exceed 100,000 x109/L 5day wash ; b . Arm C : No minimum washout require discontinuation ibrutinib ( BTK inhibitor ) c. Approved PI3 kinase inhibitor : Subjects may start study treatment within 3 day discontinuation approve PI3 kinase inhibitor . 14 . Persistent diarrhea malabsorption ≥ NCI CTCAE Grade 2 , despite medical management 15 . Active disease transformation ( ie , Richter 's Syndrome ) ; subject Richter 's Syndrome resolve &gt; 2 year sign ICD eligible . 16 . Known acute chronic pancreatitis 17 . Pregnant lactating female Arm B ( CC122 combination ibrutinib ) : 18 . Prior treatment BTK inhibitor 19 . Presence transfusiondependent thrombocytopenia history bleed disorder clinical condition ( eg , gastrointestinal bleed constitutional disorder ) may increase risk lifethreatening bleed thrombocytopenic 20 . History stroke intracranial hemorrhage within 6 month prior sign ICD 21 . Medications strong inhibitor inducer CYP3A4/5 ( eg , itraconazole , ketoconazole , clarithromycin , ritonavir , phenytoin , pentobarbital , rifampin ) change ; subject change medication must exclude . 22 . Use concomitant anticoagulation warfarin vitamin K antagonists prohibit , treatment agent 7 day prior sign ICD . The use anticoagulant ( eg , heparin ) antiplatelet agent allow per investigator 's discretion . Arm C ( CC122 combination obinutuzumab ) : 23 . Hypersensitivity obinutuzumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CC-122</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Obinutuzumab</keyword>
	<keyword>GA101</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
</DOC>